Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.

MLA

Goyal, Amrita, et al. “Variable Loss of CD30 Expression by Immunohistochemistry in Recurrent Cutaneous CD30+ Lymphoid Neoplasms Treated with Brentuximab Vedotin.” Journal of Cutaneous Pathology, vol. 46, no. 11, Nov. 2019, pp. 823–29. EBSCOhost, https://doi.org/10.1111/cup.13545.

APA

Goyal, A., Patel, S., Goyal, K., Morgan, E. A., & Foreman, R. K. (2019). Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. Journal of Cutaneous Pathology, 46(11), 823–829. https://doi.org/10.1111/cup.13545

Chicago

Goyal, Amrita, Sanjay Patel, Kavita Goyal, Elizabeth A. Morgan, and Ruth K. Foreman. 2019. “Variable Loss of CD30 Expression by Immunohistochemistry in Recurrent Cutaneous CD30+ Lymphoid Neoplasms Treated with Brentuximab Vedotin.” Journal of Cutaneous Pathology 46 (11): 823–29. doi:10.1111/cup.13545.